Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: A phase I/II study

Haematologica

Volumn 99, Issue 1, 2014, Pages 54-59

  Walter, Roland B ^a,b   Medeiros, Bruno C ^c   Gardner, Kelda M ^a   Orlowski, Kaysey F ^a   Gallegos, Leonel ^c   Scott, Bart L ^a,b   Hendrie, Paul C ^a,b   Estey, Elihu H ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE FACTORS; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; FEMALE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84892614202     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096545     Document Type: Article

References (26)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
2. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26): 6198-208.
3. Cowan AJ, Laszlo GS, Estey EH, Walter RB. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013;18(4): 1311-34.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9): 769-84.
5. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009;15(12):3970-7.
6. ten Cate B, Samplonius D F, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia. 2007;21(2):248-52.
7. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20(12):2093-101.
8. Kurimoto M, Matsuoka H, Hanaoka N, Uneda S, Murayama T, Sonoki T, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27(1):233-5.
9. Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49(11):2141-7.
10. Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2009;84 (9):599-600.
11. Bayraktar UD, Domingo GC, Schmit J, Pereira D. Azacitidine combined with gem-tuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2011;52(5): 913-5.
12. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271-9.
13. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
14. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.
15. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-9.
16. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
18. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3): 478-90.
19. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54(5):829-33.
20. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83(7):1760-8.
21. van der Velden VHJ, Te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger AS, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internaliza-tion by leukemic and normal myeloid cells. Blood. 2001;97(10):3197-204.
22. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66-71.
23. Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytara-bine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association. Am J Hematol. 2012;87 (1):62-5.
24. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379 (9825):1508-16.
25. Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, et al. Decitabine and gemtuzumab ozogamicin in acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood. 2012;120(21):abstract 3619.
26. Ball ED, Medeiros BC, Balaian L, Roque T, Corringham S, Rajwanshi R, et al. Update of a phase I/II trial of 5-azacytidine prior to gemtuzumab ozogamicin (GO) for patients with relapsed acute myeloid leukemia with correlative biomarker studies. Blood. 2010; 116(21):abstract 3286.